Changes to interests of a significant shareholder

RNS Number : 2102J

Alliance Pharma PLC

26 June 2017

 

For immediate release

26 June 2017

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Changes to interests of a significant shareholder

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, has received a notification of a change in the interests of a significant shareholder.   In accordance with AIM rule 17, the following details are now notified:

(a)  Identity of the significant shareholder: Mr Nigel Wray

(b)  Date of disclosure: 26 June 2017

(c)   Date of relevant change: 23 June 2017

(d)  Price, amount and class: 8,000,000 ordinary shares of 1p each; price not disclosed

(e)  Nature of transaction: sale of shares

(f)   Nature and extent of significant shareholder's interest: direct and indirect interests

(g)  Resultant shareholding: 1.59% (direct) and 1.59% (indirect) = 3.18% total

In compliance with DTR5, a copy of the notification received from this investor is appended.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Andrew Franklin, Chief Financial Officer
Rob Bellhouse, Company Secretary
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii			ALLIANCE PHARMA PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights				√
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Full name of person(s) subject to the notification obligation: iii		NIGEL WRAY
4. Full name of shareholder(s)  (if different from 3.):iv		UBS PRIVATE BANKING NOMINEES LTD ROY NOMINEES LIMITED
5. Date of the transaction and date on which the threshold is crossed or reached: v		23 June 2017
6. Date on which issuer notified:		26 June 2017
7. Threshold(s) that is/are crossed or reached: vi, vii		3%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of  voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary shares GB0031030819

23,092,593

23,092,593

7,551,269

7,551,269

7,541,324

1.59%

1.59%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

15,092,593

3.18%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi
Nigel William Wray has a beneficial interest in shares in Alliance Pharma Plc held by the following nominees 7,551,269 held by UBS Private Banking Nominees Ltd The family of Nigel Wray maintains a beneficial interest in the shares held by Roy Nominees Limited   - 7,541,324
Proxy Voting:
10. Name of the proxy holder:		N/A
11. Number of voting rights proxy holder will cease to hold:		N/A
12. Date on which proxy holder will cease to hold voting rights:		N/A
13. Additional information:	Figures are based on a total number of voting          rights of 474,307,589
14. Contact name:	Nigel Wray
15. Contact telephone number:	020 7647 7647

 

END

 

 

HOLPGUQPQUPMGQQ